Positive data from novel human challenge models

Summary by AI BETAClose X

hVIVO plc announced positive data from newly developed human challenge models presented at the ESWI and World Vaccine Congress Europe conferences. The company showcased its world-first contemporary-strain hMPV challenge model, its first commercially available Omicron BA5 SARS-CoV-2 challenge model, and a robust RSV B challenge model, all demonstrating acceptable safety profiles and readiness for vaccine and antiviral trials. These developments enhance hVIVO's capability to accelerate novel therapeutic development and meet evolving industry demands.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings